BEIJING - Like a stone being thrown into a pool of calm water, the China FDA released on March 9 “Document 51, Reform Plans for Chemical Drug Registration”, stirring up immediate reactions from the pharma industry.
Although the CFDA had in late 2015 decided to narrow the definition of "new drugs", the agency provides further details...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?